Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Highlights • The overall safety profile of adjuvant abemaciclib in combination with ET is consistent with its established safety profile. • Abemaciclib+ET has an acceptable, reversible, and manageable safety profile in high risk EBC. • The patient-reported outcomes support the tolerability of abemaciclib+ET in EBC. • Abemaciclib demonstrated a positive benefit-risk in patients with HR+, HER2- high risk EBC.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
